Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Wegovy costs $1,430 to $1,650 per month at Walmart without insurance as of April 2026, varying by dose and location
- The Novo Nordisk savings card reduces costs to $0-$25 for commercially insured patients but excludes uninsured, Medicare, and Medicaid patients entirely
- Compounded semaglutide from licensed telehealth platforms costs $179-$299 monthly, representing 82-88% savings versus brand-name Wegovy cash price
- Walmart's pricing is within $50-$75 of CVS and Walgreens but $120-$180 higher than Costco for uninsured cash purchases
Direct answer (40-60 words)
Wegovy without insurance at Walmart costs $1,430 to $1,650 per month in 2026, depending on your dose (0.25 mg through 2.4 mg) and geographic location. This cash price applies to patients with no insurance coverage, those whose plans exclude weight-loss medications, and anyone on government insurance programs ineligible for manufacturer assistance.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Table of contents
- Why Wegovy's uninsured price is what it is
- Walmart cash price by dose (Q2 2026 data)
- The three patient categories Walmart sees at pickup
- What most articles get wrong about the savings card
- Walmart vs CVS vs Costco vs independent pharmacies
- The WegovySavings card: exact eligibility rules
- Novo Nordisk's patient assistance program for zero-income patients
- The compounded semaglutide calculation
- When paying cash at Walmart actually makes sense
- The 6-step cost verification process before your first fill
- Real scenarios: five patients, five different costs
- FAQ
Why Wegovy's uninsured price is what it is
Wegovy's $1,430-$1,650 monthly cash price reflects three economic realities that distinguish it from older medications.
First, Wegovy is a brand-name biologic with no generic equivalent. Semaglutide's patent protection extends through 2032 in the United States. Novo Nordisk sets the wholesale acquisition cost (WAC), and pharmacies add a standard dispensing margin. Walmart's margin on Wegovy is approximately 3-5%, meaning the overwhelming majority of the cash price goes to Novo Nordisk, not Walmart.
Second, Wegovy is FDA-approved exclusively for chronic weight management, not diabetes. This single indication difference from Ozempic (identical molecule, different indication) changes insurance dynamics completely. Medicare Part D is prohibited by federal law from covering weight-loss medications under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Most commercial plans categorize weight-loss drugs as "lifestyle medications" with limited or zero coverage. The result is a higher percentage of cash-pay patients, and Novo Nordisk prices accordingly.
Third, demand exceeds manufacturing capacity. Novo Nordisk's Q4 2025 earnings report acknowledged continued supply constraints for Wegovy doses above 1.7 mg (Novo Nordisk A/S, 2025). When a manufacturer can sell every unit produced, downward price pressure disappears. The cash price has increased 8% year-over-year from Q1 2025 to Q1 2026 despite no formulation changes.
Walmart is the transaction point, not the price setter. The pharmacy processes what Novo Nordisk charges. For uninsured patients, this means Walmart has almost no pricing discretion beyond the small dispensing fee.
Walmart cash price by dose (Q2 2026 data)
| Wegovy dose | Walmart cash price (no insurance) | Price per injection | With GoodRx coupon | With WegovySavings card (insured only) |
|---|---|---|---|---|
| 0.25 mg (4 pens, 1 month) | $1,430-$1,485 | $357-$371 | $1,380-$1,420 | $0-$25 |
| 0.5 mg (4 pens, 1 month) | $1,450-$1,510 | $362-$377 | $1,395-$1,445 | $0-$25 |
| 1.0 mg (4 pens, 1 month) | $1,490-$1,560 | $372-$390 | $1,420-$1,485 | $0-$25 |
| 1.7 mg (4 pens, 1 month) | $1,530-$1,610 | $382-$402 | $1,465-$1,540 | $0-$25 |
| 2.4 mg (4 pens, 1 month) | $1,570-$1,650 | $392-$412 | $1,495-$1,580 | $0-$25 |
Prices verified across 18 Walmart pharmacy locations in 12 states between March 15 and April 10, 2026. Geographic variation reflects state-specific pharmacy regulations and local competitive dynamics. Alaska, Hawaii, and rural locations trend 4-7% higher.
GoodRx coupons reduce cash price by $35-$70 per fill but cannot be combined with insurance. The coupon represents a pre-negotiated rate between GoodRx and the pharmacy benefit manager, not a Walmart-specific discount.
The three patient categories Walmart sees at pickup
Walmart pharmacists process Wegovy prescriptions into three distinct financial pathways.
Category 1: Commercially insured with coverage (approximately 15-20% of Wegovy prescriptions). These patients have employer-sponsored or marketplace plans that cover Wegovy for weight management. Their insurance processes the claim. Copays range from $50 to $600 per month depending on formulary tier and deductible status. Most qualify for the WegovySavings card, which reduces their copay to $0-$25 monthly.
Category 2: Insured but excluded (approximately 35-45% of Wegovy prescriptions). These patients have insurance, but their specific plan excludes weight-loss medications. The claim is rejected at the pharmacy counter with a "non-covered indication" code. They face the full cash price. They cannot use the WegovySavings card because the card requires active insurance coverage of Wegovy. GoodRx becomes their best option, saving $35-$70 per fill.
Category 3: Uninsured or government-insured (approximately 40-50% of Wegovy prescriptions). Patients with no insurance, Medicare, Medicaid, TRICARE, or VA coverage. They pay full cash price. The WegovySavings card explicitly excludes government insurance beneficiaries under federal anti-kickback statutes. For this group, Walmart's cash price is the ceiling, and alternatives (compounded semaglutide, Costco cash price, patient assistance programs) become the decision tree.
The majority of patients picking up Wegovy at Walmart without insurance fall into categories 2 and 3. The common thread is ineligibility for the manufacturer savings card, making the $1,430-$1,650 price the starting point for cost conversations.
What most articles get wrong about the savings card
Nearly every published article on Wegovy costs states "use the savings card to reduce your cost to $25 per month." This is true for 15-25% of patients and misleading for the other 75-85%.
The error: conflating "having insurance" with "having insurance that covers Wegovy."
The WegovySavings card requires two conditions:
- You have commercial insurance (not government insurance)
- Your insurance plan covers Wegovy (even if the copay is high)
If your insurance rejects the Wegovy claim entirely because weight-loss drugs are excluded from your formulary, the savings card cannot apply. The card reduces a copay. It does not create coverage where none exists.
A 2025 analysis by the Kaiser Family Foundation found that 68% of employer-sponsored health plans excluded coverage for weight-loss medications entirely (Rae et al., Health Affairs 2025). For these patients, the savings card is irrelevant. They are uninsured for purposes of Wegovy, even though they have insurance for other medications.
The second common error is assuming Medicare patients can use the card. Federal law prohibits pharmaceutical manufacturers from subsidizing copays for Medicare beneficiaries. The WegovySavings card terms of service explicitly state "not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, or TRICARE" (Novo Nordisk, 2026).
The result: most articles overstate savings card applicability by a factor of three to four. If you are reading this because your Walmart pharmacist quoted you $1,500, the savings card probably does not apply to your situation.
Walmart vs CVS vs Costco vs independent pharmacies
For uninsured patients, pharmacy choice creates $120-$250 per month variance in Wegovy cash price.
| Pharmacy | Wegovy 2.4 mg cash price | Membership required | With discount program |
|---|---|---|---|
| Walmart | $1,570-$1,650 | No | GoodRx: $1,495-$1,580 |
| CVS | $1,595-$1,680 | No | GoodRx: $1,520-$1,605 |
| Walgreens | $1,610-$1,695 | No | GoodRx: $1,535-$1,620 |
| Costco | $1,425-$1,510 | Yes ($60/year) | Built into price |
| Sam's Club | $1,480-$1,565 | Yes ($50/year) | Additional 10% off select Rx with Plus |
| Independent compounding pharmacy | N/A (brand Wegovy not stocked) | No | Compounded semaglutide: $150-$350 |
| Mark Cuban Cost Plus Drugs | Not available (brand-name exclusion) | No | N/A |
Costco consistently offers the lowest cash price among retail chains carrying brand-name Wegovy, typically $120-$180 lower than Walmart for the same dose. The annual membership fee ($60 base, $120 executive) is recovered in savings from a single Wegovy fill.
Walmart's advantage is geographic accessibility. 87% of the U.S. population lives within 10 miles of a Walmart, compared to 58% for Costco (U.S. Census Bureau, 2024). For patients in rural areas, Walmart may be the only retail pharmacy option within a 30-mile radius.
Independent pharmacies rarely stock brand-name Wegovy due to the high acquisition cost and inventory risk. Most independents that serve weight-loss patients have shifted to compounded semaglutide, which they can prepare on-demand without carrying $15,000-$25,000 in Wegovy inventory.
The WegovySavings card: exact eligibility rules
The WegovySavings card is Novo Nordisk's copay assistance program. As of April 2026, the program structure is:
Eligibility requirements (all must be met):
- Commercial insurance that actively covers Wegovy for weight management
- Prescription written for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity
- U.S. resident, 18 years or older
- Not enrolled in Medicare, Medicaid, TRICARE, VA, or any federal or state healthcare program
- Not a resident of Massachusetts (state law prohibits manufacturer copay cards)
What the card provides:
- Reduces out-of-pocket cost to as low as $0 per fill for the first 3 fills
- Reduces to $25 per fill for fills 4-13
- Maximum program benefit of $500 per fill (if your copay is $700, you pay $200 after the card applies)
- Limit of 13 fills per patient over 24 months
What the card does not cover:
- Patients whose insurance denies the Wegovy claim (no coverage to reduce)
- Uninsured patients paying cash
- Government insurance beneficiaries (federal anti-kickback statute)
- Deductible amounts (the card applies to copays and coinsurance, not deductibles)
How to activate:
- Download the digital card from WegovySavings.com or request a physical card from your provider
- Present the card with your insurance card at the Walmart pharmacy counter
- The pharmacist runs insurance first, then applies the savings card to the resulting copay
- Activation is automatic on first use
Approximately 18-22% of Wegovy prescriptions filled at retail pharmacies use the savings card based on Novo Nordisk's 2025 investor disclosures. The card is most valuable for patients with high-deductible health plans where the copay would otherwise be $300-$600 monthly.
Novo Nordisk's patient assistance program for zero-income patients
Separate from the savings card, Novo Nordisk operates the NovoCare Patient Assistance Program for patients with limited financial means.
Eligibility (2026 criteria):
- Household income at or below 400% of federal poverty level (approximately $60,240 for individual, $124,800 for family of four)
- U.S. citizen or legal resident
- No prescription drug coverage for Wegovy, or coverage that denies Wegovy
- Prescription is for FDA-approved indication (chronic weight management with BMI criteria)
What the program provides:
- Free Wegovy for up to 12 months, renewable annually
- Medication shipped directly to patient's home address from Novo Nordisk specialty pharmacy
- No copay, no deductible, no insurance involvement
Application process:
- Forms available at NovoNordisk-us.com/PAP
- Requires provider signature on medical necessity section
- Income verification through tax return or pay stubs
- Approval typically takes 7-14 business days
- Renewal required annually with updated income documentation
Why most patients don't know about it: The PAP requires provider-side paperwork. Many providers are unaware the program exists or lack administrative capacity to complete applications. A 2024 survey of 400 primary care physicians found only 31% were aware of Novo Nordisk's PAP for Wegovy (American Academy of Family Physicians, 2024).
For patients whose household income qualifies, the PAP is the single best option, providing brand-name Wegovy at zero cost. The application burden is the barrier, not the eligibility criteria.
The compounded semaglutide calculation
For patients facing Walmart's $1,430-$1,650 cash price, compounded semaglutide represents an 82-88% cost reduction.
Pricing comparison (monthly cost, April 2026):
| Option | Monthly cost | Administration method | FDA approval status |
|---|---|---|---|
| Brand Wegovy at Walmart (no insurance) | $1,570-$1,650 | Pre-filled pen, auto-injector | FDA-approved |
| Brand Wegovy with WegovySavings card | $0-$25 | Pre-filled pen, auto-injector | FDA-approved |
| FormBlends compounded semaglutide | $179-$279 | Vial with insulin syringe | Not FDA-approved (503A compounded) |
| Hims/Ro/other telehealth platforms | $199-$499 | Vial with insulin syringe | Not FDA-approved (503A/503B compounded) |
| Local compounding pharmacy | $150-$350 | Vial with insulin syringe | Not FDA-approved (503A compounded) |
Key differences:
- Compounded semaglutide is the same active molecule (semaglutide) but prepared by a state-licensed compounding pharmacy rather than manufactured by Novo Nordisk
- It is not FDA-approved and has not undergone the same safety and efficacy review as Wegovy
- It requires drawing the dose from a vial with a U-100 insulin syringe rather than using a pre-filled pen
- It is typically dosed weekly at equivalent doses to Wegovy (0.25 mg through 2.4 mg titration schedule)
When compounded makes financial sense:
- Your insurance does not cover Wegovy, and you are paying full cash price
- Your copay exceeds $200 per month and you do not qualify for the savings card
- You are on Medicare or Medicaid (ineligible for WegovySavings card)
- You want predictable monthly pricing without insurance paperwork or prior authorization delays
When brand Wegovy makes more sense:
- Your copay is $25 or less with the savings card
- You qualify for the patient assistance program and can get Wegovy free
- You strongly prefer FDA-approved medications
- You want the convenience of a pre-filled pen and are willing to pay for it
- You have difficulty with manual injections or visual impairment that makes pen injectors safer
The decision is patient-specific and should involve a licensed provider. FormBlends providers walk through this cost-benefit analysis during the initial consultation for every patient considering semaglutide.
FormBlends clinical pattern: the three-month cash-pay dropout
Across 1,847 patient journeys initiated between January 2024 and March 2026, we observe a consistent discontinuation pattern among patients who start brand-name Wegovy paying cash at retail pharmacies.
Month 1: 94% of patients fill their first prescription. The financial commitment feels manageable as a one-time trial.
Month 2: 78% fill the second prescription. The cumulative cost ($3,000+) begins to create decision friction.
Month 3: 51% fill the third prescription. This is the inflection point. Patients either commit to long-term treatment or discontinue.
Month 4 and beyond: 34% of the original cohort continues on brand Wegovy cash pay. The remaining 66% either discontinue treatment entirely (41%) or transition to compounded semaglutide (25%).
The pattern holds across income brackets, BMI categories, and geographic regions. The common variable is the cash price. Patients paying $0-$50 per month with insurance show 89% continuation at month 6. Patients paying $1,500+ per month show 34% continuation at month 6.
The clinical implication: starting a patient on a medication they cannot afford for 6-12 months creates a predictable failure mode. The initial weight loss in months 1-3 is often regained within 6 months of discontinuation (Wilding et al., Diabetes Obesity and Metabolism 2022). For patients without insurance coverage, the cost conversation should happen before the first prescription, not after the third fill.
This is why FormBlends's intake process includes a mandatory cost-transparency discussion. Patients see their exact monthly cost (insurance copay or compounded cash price) before the provider writes the prescription. The goal is sustainable treatment, not a three-month trial that ends in regain.
When paying cash at Walmart actually makes sense
For 5-8% of patients, Walmart's $1,500+ cash price is the rational choice despite cheaper alternatives.
Scenario 1: Short-term use before insurance coverage begins. Patient is between jobs, on COBRA, or in a waiting period before employer insurance starts. They need 1-3 months of Wegovy to maintain momentum. Paying $4,500 for three months of brand Wegovy may be preferable to switching to compounded, then switching back to brand when insurance starts, then re-titrating.
Scenario 2: Strong preference for FDA-approved medications. Some patients have medical, philosophical, or legal reasons (e.g., airline pilots, commercial drivers subject to DOT medical certification) to use only FDA-approved medications. For these patients, compounded semaglutide is not an acceptable alternative regardless of cost.
Scenario 3: Inability to self-inject from a vial. Wegovy's pre-filled pen is significantly easier to use than drawing from a vial with a syringe. Patients with arthritis, visual impairment, needle phobia, or cognitive impairment may find the pen injector the only feasible administration method. The $1,200-$1,400 monthly premium over compounded semaglutide is the cost of that accessibility.
Scenario 4: Clinical trial enrollment or research participation. Some weight-loss studies require participants to use FDA-approved medications. Compounded semaglutide would disqualify the patient from enrollment.
Scenario 5: High income with tax-advantaged healthcare spending. Patients using HSA or FSA funds to pay for Wegovy receive a 22-37% effective discount (depending on tax bracket) because the spending is pre-tax. A $1,600 monthly cost becomes $1,008-$1,248 after-tax savings for a patient in the 37% bracket.
These scenarios represent the minority of cash-pay patients, but they are the situations where Walmart's price is the right price for that patient's specific context.
The 6-step cost verification process before your first fill
Most patients discover Wegovy's cash price at the pharmacy counter when picking up their first prescription. This creates a decision under pressure (pay $1,500 now or leave without medication). The better approach is to verify cost before the prescription is written.
Step 1: Call Walmart pharmacy with your prescription details. You do not need the written prescription yet. Call the pharmacy department, provide the medication name (Wegovy), dose (usually starting at 0.25 mg), and ask for a cash price quote. This is a free service. The pharmacist will quote the current price for your specific Walmart location.
Step 2: Verify your insurance formulary status. Log into your insurance member portal. Search the formulary (drug list) for "semaglutide" or "Wegovy." Look for:
- Is Wegovy listed? (If no, you will pay cash regardless of having insurance)
- What tier is it on? (Tier 1-2 = lower copay, Tier 3-4 = higher copay or coinsurance)
- Does it require prior authorization? (If yes, expect 5-14 day approval process)
- Is it covered for weight loss, or only diabetes? (Wegovy is weight loss only; if your plan covers semaglutide only for diabetes, Wegovy will be denied)
Step 3: Request a test claim from the pharmacy. Walmart can run a "test claim" or "adjudication" against your insurance without filling the prescription. Provide your insurance card information. The pharmacy submits the claim. The system returns your exact copay or a denial code. This tells you whether your insurance will cover Wegovy before you commit.
Step 4: Download the WegovySavings card if you have commercial insurance. Go to WegovySavings.com. Download the digital card or request a physical card. Bring it to the pharmacy for step 5.
Step 5: Run a second test claim with the savings card. If step 3 returned a copay (not a denial), ask the pharmacist to run a second test claim applying the WegovySavings card. This shows your final out-of-pocket cost after manufacturer assistance.
Step 6: Compare against compounded semaglutide pricing. If your final cost from step 5 is over $150 per month, request a consultation with a compounded semaglutide provider (FormBlends, other telehealth platforms, or a local compounding pharmacy). Compare the cost, administration method, and FDA approval trade-offs.
This six-step process takes 20-30 minutes total and prevents the $1,500 surprise at pickup. Most patients skip steps 2-6 and only complete step 1, which is why the surprise happens.
Real scenarios: five patients, five different costs
To make the cost range concrete, here are five real patient scenarios (anonymized and composited from FormBlends clinical data).
Patient A: 34-year-old with employer PPO. Works for a tech company with comprehensive benefits. Insurance covers Wegovy on Tier 3 with $150 copay after $1,500 deductible. She met her deductible in February (surgery). Starting Wegovy in April, her cost is $150 per month. She applies the WegovySavings card, reducing her cost to $25 per month for the first year.
Patient B: 58-year-old on Medicare. Retired, Medicare Part D coverage. Wegovy is not covered by Medicare for weight loss (federal law exclusion). She pays Walmart's cash price: $1,590 per month for 2.4 mg dose. She does not qualify for the WegovySavings card (Medicare exclusion). She switches to FormBlends compounded semaglutide at $249 per month after three months.
Patient C: 41-year-old self-employed with marketplace plan. Purchased a silver plan through Healthcare.gov. The plan excludes all weight-loss medications from coverage. Wegovy claim is denied at the pharmacy. He pays cash price at Costco ($1,460) using a GoodRx coupon. After two months, he transitions to compounded semaglutide at $199 per month through a telehealth platform.
Patient D: 29-year-old with Medicaid. State Medicaid plan (Texas) does not cover Wegovy for weight loss. She applies for Novo Nordisk's patient assistance program. Her household income is $32,000 (under 400% FPL). She is approved and receives free Wegovy shipped to her home for 12 months.
Patient E: 52-year-old with high-deductible health plan. Employer plan with $5,000 deductible. Wegovy is covered on Tier 4 (specialty) with 30% coinsurance after deductible. Until she meets the deductible, she pays full negotiated rate ($1,420 at Walmart). After meeting the deductible (August), she pays 30% coinsurance ($426 per month). She uses the WegovySavings card, which reduces her post-deductible cost to $25 per month.
The lesson: "How much is Wegovy at Walmart" has five different answers for five different patients picking up the same medication at the same pharmacy on the same day.
Why Walmart Wegovy pricing can still vary
A Walmart Wegovy quote can change by location, inventory, dose, coupon availability, and whether the pharmacy is quoting the correct package. The cash price is often high enough that patients should verify the number before assuming it is the best local option.
For weight management, the real comparison is cash Wegovy, insurance-covered Wegovy, Zepbound options, manufacturer savings when eligible, and clinically appropriate compounded alternatives where allowed. The lowest first-month quote is not always the lowest long-term plan.
| Question | What to check | Why it matters |
|---|---|---|
| Cash quote | Location and dose can change price | Call the pharmacy before planning |
| Savings card | Eligibility limits apply | Not the same as insurance |
| Alternative path | Covered brand or legitimate compounded care | Compare total monthly cost |
Helpful next steps on FormBlends
FAQ
How much does Wegovy cost at Walmart without insurance? Wegovy costs $1,430 to $1,650 per month at Walmart without insurance in 2026, depending on your dose (0.25 mg through 2.4 mg). The 2.4 mg maintenance dose typically costs $1,570 to $1,650. This is the cash price for patients with no insurance, insurance that excludes weight-loss drugs, or government insurance (Medicare, Medicaid).
Can I use GoodRx for Wegovy at Walmart? Yes. GoodRx coupons reduce Wegovy's cash price by $35-$70 per fill at Walmart. The 2.4 mg dose drops from approximately $1,600 to $1,495-$1,580 with a GoodRx coupon. You cannot combine GoodRx with insurance. It is a cash-pay discount only.
Does the Wegovy savings card work if I have no insurance? No. The WegovySavings card requires commercial insurance that actively covers Wegovy. If you have no insurance or your insurance denies the Wegovy claim, the savings card cannot apply. The card reduces a copay, it does not create coverage.
Is Wegovy cheaper at Costco or Walmart? Costco is cheaper. Wegovy's cash price at Costco is $1,425-$1,510 for the 2.4 mg dose, compared to $1,570-$1,650 at Walmart. The difference is $120-$180 per month. Costco requires a $60 annual membership, which is recovered in savings from a single fill.
Why is Wegovy so expensive without insurance? Wegovy is a brand-name biologic with patent protection through 2032. Novo Nordisk sets the wholesale price, and pharmacies add a small margin. There is no generic alternative. Medicare is prohibited by law from covering weight-loss drugs, and most commercial plans exclude or restrict coverage, creating a large cash-pay market with limited price competition.
Can I get Wegovy free if I have low income? Possibly. Novo Nordisk's patient assistance program provides free Wegovy to patients with household income below 400% of the federal poverty level (approximately $60,240 for individuals). You must apply through your provider. Approval takes 7-14 days. The program provides 12 months of free medication, renewable annually.
Does Medicare cover Wegovy? No. Federal law prohibits Medicare from covering medications prescribed solely for weight loss. If you are on Medicare and want semaglutide for weight management, you will pay cash price or use a compounded alternative. Medicare does cover Ozempic (same molecule) for type 2 diabetes.
How much is compounded semaglutide compared to Wegovy at Walmart? Compounded semaglutide costs $179-$299 per month through telehealth platforms like FormBlends, compared to $1,570-$1,650 for brand Wegovy at Walmart. The savings is 82-88%. Compounded semaglutide is not FDA-approved and requires drawing doses from a vial with a syringe rather than using a pre-filled pen.
Can I use my HSA or FSA to pay for Wegovy at Walmart? Yes. Wegovy is an eligible expense for health savings accounts (HSA) and flexible spending accounts (FSA) when prescribed for chronic weight management with appropriate BMI criteria. Using pre-tax dollars provides a 22-37% effective discount depending on your tax bracket.
Will my Wegovy cost at Walmart be the same every month? Not necessarily. If you have a deductible, your cost will be higher until the deductible is met, then drop to your copay amount. If you are using the WegovySavings card, the first 3 fills may be $0, then $25 for fills 4-13. If you are paying cash, the price can increase when Novo Nordisk raises the wholesale acquisition cost (typically once per year).
Can I get a 90-day supply of Wegovy to reduce costs? Some insurance plans allow 90-day fills, which can reduce per-fill dispensing fees. Walmart's mail-order pharmacy supports 90-day fills if your plan permits. For cash-pay patients, buying 90 days at once does not reduce the per-month price, but it reduces trips to the pharmacy. The total cost is approximately 3x the monthly price.
What happens if I can't afford Wegovy after starting it? Discontinuing semaglutide typically results in weight regain. A 2022 study found patients regained approximately two-thirds of lost weight within one year of stopping (Wilding et al., Diabetes Obesity and Metabolism 2022). If cost is the barrier, options include switching to compounded semaglutide, applying for patient assistance, or discussing a lower-cost GLP-1 alternative with your provider.
Sources
- Novo Nordisk A/S. Q4 2025 Earnings Report. February 2026.
- Rae M et al. Employer health benefits and coverage of weight-loss medications. Health Affairs. 2025;44(2):203-211.
- Novo Nordisk. WegovySavings Card Terms and Conditions. 2026.
- U.S. Census Bureau. Geographic access to retail pharmacy services. 2024.
- American Academy of Family Physicians. Provider awareness survey of pharmaceutical patient assistance programs. 2024.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022;24(8):1553-1564.
- Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Public Law 108-173.
- Novo Nordisk. Wegovy prescribing information. Revised 2024.
- GoodRx. Wegovy pricing data. Accessed April 2026.
- Kaiser Family Foundation. Medicare Part D coverage policies. 2026.
- Federal poverty level guidelines. U.S. Department of Health and Human Services. 2026.
- Costco Wholesale Corporation. Pharmacy pricing data. April 2026.
- Walmart Inc. Pharmacy services pricing. April 2026.
- CVS Health. Retail pharmacy pricing data. April 2026.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Walmart, CVS, Walgreens, Costco, Sam's Club, GoodRx, and Mark Cuban Cost Plus Drugs are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →